Health Stock Movers: Genpact Shares Receive Buy Rating, Amylin Risky, Celgene Price Target Rises

In market action on Thursday, traders continued to buy equities on doses of good earnings news and improving economic data. Here are a few companies in the healthcare sector analysts reviewed and provided insights in the marketplace today:

Genpact Ltd. (NYSE:G): Kaufman Bros. sees nice entry point on Genpact weakness. Underperforming after third quarter results, Kaufman Bros. cites the company’s differentiated analytics and believes its re-engineering business is executing smartly. The firm maintains a Buy with a $20 target.

Amylin Pharmaceuticals, Inc. (NASDAQ:AMLN): Goldman says Amylin is still a risk.   Goldman thinks Amylin’s diabetes drug Bydureon has only a 70 percent chance of approval by the Food and Drug Administration (FDA).  The firm feels FDA might provide a third response letter that could have minor issues.  Either way, Goldman views the company as risky, depending on whether or not FDA has enough data or wants more. The firm rates AMLN Sell with a $7 target.

Celgene Corporation (NASDAQ:CELG): Revlimid will be subject to some regulatory decisions this year. Oppenheimer says buy Revlimid before the descisions. The firm expects the company’s to top its guidance with “outstanding” operational results. Oppenheimer maintains an Outperform and raises Celgene target from $74 to $84.

Featured Reading: Big Banks Report Mixed Results in Weak Earnings Season>>